Literature DB >> 16631131

The fibroblast growth factor system and mood disorders.

Cortney A Turner1, Huda Akil, Stanley J Watson, Simon J Evans.   

Abstract

Recent evidence now suggests the involvement of the fibroblast growth factor (FGF) system in mood disorders. Specifically, several members of the FGF family have been shown to be dysregulated in individuals with major depression. In this review, we will introduce the FGF system in terms of structure and function during development, in adulthood, and in various regions and cell types. We will also review the FGF system as a mediator of neural plasticity. Furthermore, this review will summarize animal as well as human studies. The majority of animal studies have focused on stress, environmental enrichment, pharmacological manipulations, and the hippocampus. By contrast, human studies have focused on volumetric measurements, antidepressant literature, and, most recently, post-mortem microarray experiments. In summary, a reduced tone in the FGF system might alter brain development or remodeling and result in a predisposition or vulnerability to mood disorders, including major depression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631131     DOI: 10.1016/j.biopsych.2006.02.026

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  44 in total

Review 1.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

Review 2.  Fibroblast growth factors in schizophrenia.

Authors:  Afke F Terwisscha van Scheltinga; Steven C Bakker; René S Kahn
Journal:  Schizophr Bull       Date:  2009-05-08       Impact factor: 9.306

Review 3.  Implementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors.

Authors:  Italo Mocchetti; Alessia Bachis; Lee A Campbell; Valeriya Avdoshina
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-06       Impact factor: 4.147

Review 4.  Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field.

Authors:  Kjell Fuxe; Dasiel O Borroto-Escuela; Wilber Romero-Fernandez; Miklós Palkovits; Alexander O Tarakanov; Francisco Ciruela; Luigi F Agnati
Journal:  Neuropsychopharmacology       Date:  2013-09-06       Impact factor: 7.853

Review 5.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

6.  Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression.

Authors:  R Bernard; I A Kerman; R C Thompson; E G Jones; W E Bunney; J D Barchas; A F Schatzberg; R M Myers; H Akil; S J Watson
Journal:  Mol Psychiatry       Date:  2010-04-13       Impact factor: 15.992

7.  Antidepressant-like effects of intracerebroventricular FGF2 in rats.

Authors:  Cortney A Turner; Edny L Gula; Larry P Taylor; Stanley J Watson; Huda Akil
Journal:  Brain Res       Date:  2008-06-14       Impact factor: 3.252

Review 8.  Target identification for CNS diseases by transcriptional profiling.

Authors:  C Anthony Altar; Marquis P Vawter; Stephen D Ginsberg
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

Review 9.  The fibroblast growth factor family: neuromodulation of affective behavior.

Authors:  Cortney A Turner; Stanley J Watson; Huda Akil
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

Review 10.  The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression.

Authors:  Michael Maes; Raz Yirmyia; Jens Noraberg; Stefan Brene; Joe Hibbeln; Giulia Perini; Marta Kubera; Petr Bob; Bernard Lerer; Mario Maj
Journal:  Metab Brain Dis       Date:  2008-12-16       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.